Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Beam Therapeutics (BEAM) Stock Price & Analysis
1,132 Followers
BEAM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.95 - $49.50
Previous Close$24.31
Volume1.44M
Average Volume (3M)1.48M
Market Cap
$1.99B
Enterprise Value$1.72B
Total Cash (Recent Filing)$435.89M
Total Debt (Recent Filing)$172.69M
Price to Earnings (P/E)-12.7
Beta2.04
Next Earnings
May 07, 2024EPS Estimate
-$1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding81,657,714
10 Day Avg. Volume1,454,497
30 Day Avg. Volume1,481,824
Standard Deviation0.26
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)5.56
Price to Cash Flow (P/CF)3.90
P/FCF Ratio4.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.56
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda-15.49
Forecast
1Y Price Target
$48.00Price Target Upside97.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Beam Therapeutics News
PremiumStock Analysis & Ideas
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe event leading to the trial pause is associated with the lipid nanoparticle used, not the base-editing technology itself, suggesting confidence in the core technology's safety.
Financial HealthBeam reported a strong cash position with a runway into 2027, indicating the company's solid financial foundation and ability to fund future research and development.
Innovation And Market PotentialBeam's ESCAPE platform is highly innovative and a major value driver, signaling potential for significant long-term growth as it paves the way for new treatment options.
Bears Say
Clinical TrialsVERV has paused enrollment in the Phase 1b Heart-1 trial due to safety concerns.
Financial PerformanceFor 4Q23, operating expenses were higher than expectations, signaling potential concerns over financial management.
Investor SentimentSafety concerns from the VERVE-101 trial have led to heightened investor focus on the safety of similar programs.
---
Ownership Overview
22.92% Insiders
18.23% Mutual Funds
26.95% Other Institutional Investors
31.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $16.95 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Currently, no data Available
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Feb 27, 2024. The company reported $1.73 earnings per share for the quarter, beating the consensus estimate of -$0.691 by $2.421.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -$1.42.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 81,657,715 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of $1.73 in its last earnings report, beating expectations of -$0.691. Following the earnings report the stock price went up 25.894%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is ARK Investment Management LLC. It holds Beam Therapeutics’s shares valued at 256M.
---
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.00 (97.45% Upside)
$48.00 (97.45% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 302.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.67%
12-Months-Change
Fundamentals
Return on Equity
-15.46%
Trailing 12-Months
Asset Growth
8.79%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Stock 12 Months Forecast
Average Price Target
$48.00
▲(97.45% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
-5.63%
reiterated a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -5.63% per trade.
---